Thoracic Surgeons' Beliefs and Practices on Smoking Cessation Before Lung Resection.


Journal

The Annals of thoracic surgery
ISSN: 1552-6259
Titre abrégé: Ann Thorac Surg
Pays: Netherlands
ID NLM: 15030100R

Informations de publication

Date de publication:
05 2019
Historique:
received: 08 07 2018
revised: 24 11 2018
accepted: 26 11 2018
pubmed: 27 12 2018
medline: 19 12 2019
entrez: 27 12 2018
Statut: ppublish

Résumé

Smoking is a risk factor for complications after lung resection. Our primary aim was to ascertain thoracic surgeons' beliefs and practices on smoking cessation before lung resection. An anonymous survey was emailed to 846 thoracic surgeons who participate in The Society of Thoracic Surgeons General Thoracic Surgery Database. The response rate was 23.6% (n = 200). Surgeons were divided when asked whether it is ethical to require that patients quit smoking (yes, n = 96 [48%]) and whether it is fair to have their outcomes affected by patients who do not quit (yes, n = 87 [43.5%]). Most do not require smoking cessation (n = 120 [60%]). Of those who require it, the most common required period of cessation is 2 weeks or more. Most believe that patient factors are the main barrier to quitting (n = 160 [80%]). Risk of disease progression (39% vs 17.5%, p = 0.02) and alienating patients (17.5% vs 8.8%, p = 0.04) were very important considerations of those who do not require smoking cessation versus those who do. Only 19 (9.5%) always refer to a smoking cessation program and prescribe nicotine replacement therapy and even fewer, 9 (4.5%), always refer to a program and prescribe medical therapy. Thoracic surgeons are divided on their beliefs and practices regarding smoking cessation before lung resection. Most believe patient factors are the main barrier to quitting and have concerns about disease progression while awaiting cessation. Very few surgeons refer to a smoking cessation program and prescribe nicotine replacement therapy or medical therapy.

Sections du résumé

BACKGROUND
Smoking is a risk factor for complications after lung resection. Our primary aim was to ascertain thoracic surgeons' beliefs and practices on smoking cessation before lung resection.
METHODS
An anonymous survey was emailed to 846 thoracic surgeons who participate in The Society of Thoracic Surgeons General Thoracic Surgery Database.
RESULTS
The response rate was 23.6% (n = 200). Surgeons were divided when asked whether it is ethical to require that patients quit smoking (yes, n = 96 [48%]) and whether it is fair to have their outcomes affected by patients who do not quit (yes, n = 87 [43.5%]). Most do not require smoking cessation (n = 120 [60%]). Of those who require it, the most common required period of cessation is 2 weeks or more. Most believe that patient factors are the main barrier to quitting (n = 160 [80%]). Risk of disease progression (39% vs 17.5%, p = 0.02) and alienating patients (17.5% vs 8.8%, p = 0.04) were very important considerations of those who do not require smoking cessation versus those who do. Only 19 (9.5%) always refer to a smoking cessation program and prescribe nicotine replacement therapy and even fewer, 9 (4.5%), always refer to a program and prescribe medical therapy.
CONCLUSIONS
Thoracic surgeons are divided on their beliefs and practices regarding smoking cessation before lung resection. Most believe patient factors are the main barrier to quitting and have concerns about disease progression while awaiting cessation. Very few surgeons refer to a smoking cessation program and prescribe nicotine replacement therapy or medical therapy.

Identifiants

pubmed: 30586576
pii: S0003-4975(18)31855-1
doi: 10.1016/j.athoracsur.2018.11.055
pii:
doi:

Substances chimiques

Smoking Cessation Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1494-1499

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR001860
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR001859
Pays : United States

Informations de copyright

Copyright © 2019 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Auteurs

Angelica S Marrufo (AS)

University of California Davis School of Medicine, Sacramento, California.

Benjamin D Kozower (BD)

Division of Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, Missouri.

Daniel J Tancredi (DJ)

Center for Healthcare Policy and Research, University of California Davis Health, Sacramento, California.

Miriam Nuño (M)

Department of Public Health Sciences, University of California Davis School of Medicine, Sacramento, California.

David T Cooke (DT)

Section of General Thoracic Surgery, University of California Davis Health, Sacramento, California.

Brad H Pollock (BH)

Department of Public Health Sciences, University of California Davis School of Medicine, Sacramento, California.

Patrick S Romano (PS)

Center for Healthcare Policy and Research, University of California Davis Health, Sacramento, California; Department of Internal Medicine, University of California Davis Health, Sacramento, California.

Lisa M Brown (LM)

Section of General Thoracic Surgery, University of California Davis Health, Sacramento, California. Electronic address: lmbrown@ucdavis.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH